Indications
Lartruvo is indicated in combination with doxorubicin for the treatment of adult patients with advanced soft tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin (see section 5.1).
Composition
- Active substance
- olaratumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lartruvo
- Active substance
- olaratumab
- ATC code
- L01XC27
- Therapeutic area
- Sarcoma
- Marketing authorisation holder
- Eli Lilly Nederland B.V.
- Status